Also, the company has faced additional competition with generic equivalents becoming available last year.
In this case we are again talking about using medications for off label use which a physician can do, but promoting it for such is not allowed, and thus the guilty plea here and penalty assessment. The investigation has been ongoing since 2003, so this is a long one coming to a close. BD
WASHINGTON - Two subsidiaries of pharmaceutical giant Johnson & Johnson have agreed to pay more than $81 million stemming from allegedly illegal promotion of the epilepsy drug Topamax for psychiatric uses, the Justice Department announced Thursday.
Federal drug regulators approved it as an anti-epileptic drug and for prevention of migraines.
The government says Ortho-McNeil-Janssen Pharmaceuticals Inc. will pay over $75 million for alleged illegal promotion of Topamax for a variety of psychiatric uses.
The government says that Ortho-McNeil Pharmaceutical promoted Topamax sales for unapproved psychiatric uses under a program called "Doctor-for-a-Day." Under it, Ortho-McNeil hired outside physicians who joined sales representatives in visits to health care providers and to speak at meetings and dinners about prescribing Topamax for unapproved uses.